The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma

References

• Dummer R. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006; 33:S33 - 6; http://dx.doi.org/10.1053/j.seminoncol.2005.12.021; PMID: 16516674
   PubMedGoogle Scholar
• Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768 - 85; http://dx.doi.org/10.1182/blood-2004-09-3502; PMID: 15692063
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005; 54:1153 - 61; http://dx.doi.org/10.1007/s00262-005-0699-9; PMID: 15868167
   PubMed Web of Science ®Google Scholar
• O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801 - 5; http://dx.doi.org/10.1038/nm0804-801; PMID: 15286781
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151 - 64; PMID: 7636184
   PubMed Web of Science ®Google Scholar
• Tran DQ, Ramsey H, Shevach EM. Induction of FoxP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983 - 90; http://dx.doi.org/10.1182/blood-2007-06-094656; PMID: 17644734
   PubMed Web of Science ®Google Scholar
• Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13:1299 - 307; http://dx.doi.org/10.1038/nm1652; PMID: 17922010
   PubMed Web of Science ®Google Scholar
• Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling with FoxP3 expression. Eur J Immunol 2007; 37:1817 - 26; http://dx.doi.org/10.1002/eji.200737101; PMID: 17559173
   PubMed Web of Science ®Google Scholar
• Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. FoxP3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007; 446:685 - 9; http://dx.doi.org/10.1038/nature05673; PMID: 17377532
   PubMed Web of Science ®Google Scholar
• Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126:375 - 87; http://dx.doi.org/10.1016/j.cell.2006.05.042; PMID: 16873067
   PubMed Web of Science ®Google Scholar
• Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, et al. Single-cell analysis of normal and FoxP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103:6659 - 64; http://dx.doi.org/10.1073/pnas.0509484103; PMID: 16617117
   PubMed Web of Science ®Google Scholar
• Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Sakaguchi S. Homeostatic maintenance of natural FoxP3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:723 - 35; http://dx.doi.org/10.1084/jem.20041982; PMID: 15753206
   PubMed Web of Science ®Google Scholar
• Williams LM, Rudensky AY. Maintenance of the FoxP3-dependent developmental program in mature regulatory T cells requires continued expression of FoxP3. Nat Immunol 2007; 8:277 - 84; http://dx.doi.org/10.1038/ni1437; PMID: 17220892
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated FoxP3 expression. Nature 2007; 445:766 - 70; http://dx.doi.org/10.1038/nature05479; PMID: 17220876
   PubMed Web of Science ®Google Scholar
• Wildin RS, Freitas A. IPEX and FoxP3: clinical and research perspectives. J Autoimmun 2005; 25:Suppl 56 - 62; http://dx.doi.org/10.1016/j.jaut.2005.04.008; PMID: 16243487
   PubMed Web of Science ®Google Scholar
• Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FoxP3. Nat Genet 2001; 27:20 - 1; http://dx.doi.org/10.1038/83713; PMID: 11137993
   PubMed Web of Science ®Google Scholar
• Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57:381 - 402; http://dx.doi.org/10.1146/annurev.med.57.121304.131337; PMID: 16409156
   PubMed Web of Science ®Google Scholar
• Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express FoxP3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 2004; 172:5986 - 93; PMID: 15128781
   PubMed Web of Science ®Google Scholar
• Baron U, Floess S, Wieczorek G, Baumann K, Grützkau A, Dong J, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FoxP3(+) conventional T cells. Eur J Immunol 2007; 37:2378 - 89; http://dx.doi.org/10.1002/eji.200737594; PMID: 17694575
   PubMed Web of Science ®Google Scholar
• Janson PC, Winerdal ME, Marits P, Thörn M, Ohlsson R, Winqvist O. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One 2008; 3:e1612, 2008.
   Google Scholar
• Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of FoxP3 expression in regulatory T cells by DNA methylation. J Immunol 2009; 182:259 - 73; PMID: 19109157
   PubMed Web of Science ®Google Scholar
• Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21:2512 - 8; http://dx.doi.org/10.1038/sj.leu.2404913; PMID: 17713545
   PubMed Web of Science ®Google Scholar
• Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 2008; 181:2506 - 12; PMID: 18684941
   PubMed Web of Science ®Google Scholar
• Clark RA, Shackelton JB, Watanabe R, Calarese A, Yamanaka K, Campbell JJ, et al. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Blood 2011; 117:1966 - 76; http://dx.doi.org/10.1182/blood-2010-05-287664; PMID: 21148332
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen AM, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008; 22:2230 - 9; http://dx.doi.org/10.1038/leu.2008.224; PMID: 18769452
   PubMed Web of Science ®Google Scholar
• Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, et al. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. J Invest Dermatol 2009; 129:2875 - 85; http://dx.doi.org/10.1038/jid.2009.175; PMID: 19626037
   PubMed Web of Science ®Google Scholar
• Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117:6532 - 41; http://dx.doi.org/10.1182/blood-2010-11-317321; PMID: 21493801
   PubMed Web of Science ®Google Scholar
• Schmidl C, Hansmann L, Andreesen R, Edinger M, Hoffmann P, Rehli M. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not naïve Treg. Eur J Immunol 2011; 41:1491 - 8; http://dx.doi.org/10.1002/eji.201041067; PMID: 21469109
   PubMed Web of Science ®Google Scholar
• Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12:247 - 54; http://dx.doi.org/10.1038/ni.1995; PMID: 21278738
   PubMed Web of Science ®Google Scholar
• Marzec M, Halasa K, Kasprzycka M, Wysocka M, Liu X, Tobias JW, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008; 68:1083 - 91; http://dx.doi.org/10.1158/0008-5472.CAN-07-2403; PMID: 18281483
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131:1331 - 8; http://dx.doi.org/10.1038/jid.2011.27; PMID: 21346774
   PubMed Web of Science ®Google Scholar
• Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, et al. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19:209 - 13; http://dx.doi.org/10.1038/sj.leu.2403610; PMID: 15618960
   PubMed Web of Science ®Google Scholar
• Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97:1056 - 62; http://dx.doi.org/10.1182/blood.V97.4.1056; PMID: 11159537
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102:4059 - 66; http://dx.doi.org/10.1182/blood-2003-04-1044; PMID: 12829591
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol 2003; 171:4574 - 81; PMID: 14568931
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677 - 704; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331; PMID: 18173375
   PubMed Web of Science ®Google Scholar
• Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF). Am J Dermatopathol In press
   PubMedGoogle Scholar
• Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008; 105:20852 - 7; http://dx.doi.org/10.1073/pnas.0810958105; PMID: 19088198
   PubMed Web of Science ®Google Scholar
• Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996; 93:9148 - 53; http://dx.doi.org/10.1073/pnas.93.17.9148; PMID: 8799169
   PubMed Web of Science ®Google Scholar
• Witkiewicz A, Raghunath P, Wasik A, Junkins-Hopkins JM, Jones D, Zhang Q, et al. Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol 2007; 38:462 - 7; http://dx.doi.org/10.1016/j.humpath.2006.09.012; PMID: 17239936
   PubMed Web of Science ®Google Scholar
• Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413 - 24; http://dx.doi.org/10.1002/eji.201040979; PMID: 21268011
   PubMed Web of Science ®Google Scholar